Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Barclays Downgrades Ortho Clinical Diagnostic to Equal-Weight, Lowers Price Target to $25

Author: Benzinga Newsdesk | December 27, 2021 05:12am
Barclays analyst Luke Sergott downgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from Overweight to Equal-Weight and lowers the price target from $29 to $25.

Posted In: OCDX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist